This article tickles my spidey sense. It reads like a sponsored story, or at the very least, an article written quickly and uncritically by someone who just too

This article tickles my spidey sense. It reads like a sponsored story, or at the very least, an article written quickly and uncritically by someone who just took NeuroAD's press release and talking points at face value. To wit, the article ends on this note: "It is clear that a new clinical solution for Alzheimer’s is needed and Neuronix’s NeuroAD treatment is not only a safe option, but a breakthrough in the treatment of AD." Really? That's quite a bold statement to make, given that FDA review isn't complete, and we have no longitudinal outcomes to analyze.